drugset / Trial / NCT06537349

Effects of 3% Diquafosol on Tear Film and Vision-related Quality of Life in Orthokeratology Lens Related Dry Eye

NCT06537349

Not yet recruiting 30 enrolled He Eye Hospital
NaSingle-groupOpen-labelTreatment

Summary

Investigate the effect of 3% Diquafosol on tear film and vision-related quality of life in dry eye patients wearing orthokeratology lenses(OK lens), and to provide reference for clinical treatment.This prospective, open label study will include 60 eyes of 30 OK lens related dry eye patients.Participants will receive 3% Diquafosol ophthalmic solution. The dosage for both drugs will be one drop, six times per day for 4 weeks. Pediatric Refractive Error Profiletear(PREP), tear film lipid layer (TFLL),non-invasive breakup time (NITBUT), corneoconjunctival staining score (CS), tear meniscus height (TMH), objective visual quality,ocular surface disease index (OSDI) will be assessed and compared at baseline, day-14, and day-28

Timeline

Start
2024-08-15
Primary completion
2024-12-15
Completion
2024-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Diquafosol Oligonucleotide (other) 3 % Topical

Indications